{"id":76327,"date":"2026-05-06T18:28:41","date_gmt":"2026-05-06T18:28:41","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/76327\/"},"modified":"2026-05-06T18:28:41","modified_gmt":"2026-05-06T18:28:41","slug":"wegovy-pill-debut-fattens-novo-nordisks-profit-outlook-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/76327\/","title":{"rendered":"Wegovy Pill Debut ‘Fattens’ Novo Nordisk’s Profit Outlook – Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"

The weight loss drug maker reported<\/a> first quarter sales of $15.17 billion (96.82 billion Danish kroner), beating the consensus of $11.13 billion.<\/p>\n

Sales jumped 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the U.S.<\/p>\n

The company reported adjusted earnings of $1.04 (6.63 Danish kroner), beating the consensus of 87 cents.<\/p>\n

First quarter adjusted operating profit decreased by 6% at CER to 32.86 billion Danish kroner, while reported operating profit increased by 65% at CER to 59.62 billion Danish kroner, driven by a provision reversal related to the 340B Drug Pricing Program in the U.S.<\/p>\n

Wegovy Pill Sees Strong Launch Momentum<\/p>\n

The Wegovy pill, launched in the U.S. in January 2026, recorded rapid uptake. Weekly prescriptions surpassed 200,000 by mid-April, with about 1.3 million prescriptions in the first quarter and over 2 million since launch.<\/p>\n

Quarterly sales reached 2.26 billion Danish kroner, aided by pre-launch inventory stocking by wholesalers and telehealth partners<\/a>.<\/p>\n

Pending regulatory approvals, international launches are expected<\/a> in the second half of 2026.<\/p>\n

Wegovy injectable<\/a> sales reached 20.51 billion Danish kroner, up 26% at CER.<\/p>\n

Ozempic sales jumped 32% at CER to 40.48 billion Danish kroner.<\/p>\n

Novo Nordisk Outlook Raised On GLP-1 Expectations<\/p>\n

Novo Nordisk raised its fiscal 2026 sales guidance from $40.46 billion-$44.32 billion to $42.39 billion-$46.24 billion compared to the consensus of $45.44 billion.<\/p>\n

Adjusted sales and operating profit are now projected to decline between 4% and 12% at CER, excluding the 340B-related impact<\/a>.<\/p>\n

In February, the company expected adjusted sales growth for 2026, which excludes revenue from the reversal of 340B provisions, to be -5% to -13% at CER<\/a>.<\/p>\n

Novo Nordisk Price Action<\/p>\n

NVO Price Action: Novo Nordisk shares were up 7.11% at $48.06 during premarket trading Wednesday, according to Benzinga Pro<\/a>. Over the past month, NVO has gained about 29.9% versus a 10.4% rise in the S&P 500 and is down roughly 7% year-to-date compared to the index\u2019s 5.6% gain.<\/p>\n

Image via Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"The weight loss drug maker reported first quarter sales of $15.17 billion (96.82 billion Danish kroner), beating the…\n","protected":false},"author":2,"featured_media":76328,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2085,354,2094,40869,2089,2087,2092,2088,5813,2084,272,352,2096,2100],"class_list":{"0":"post-76327","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-biotech","9":"tag-category-earnings","10":"tag-category-general","11":"tag-category-guidance","12":"tag-category-health-care","13":"tag-category-large-cap","14":"tag-category-movers","15":"tag-category-news","16":"tag-category-top-stories","17":"tag-cms-wordpress","18":"tag-novo-nordisk","19":"tag-pageisbzpro-bz","20":"tag-symbol-nvo","21":"tag-tag-why-its-moving"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116529050743874029","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/76327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=76327"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/76327\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/76328"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=76327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=76327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=76327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}